Show simple item record

dc.contributor.authorReyad, Ayman Antoun
dc.contributor.authorMishriky, Raafat
dc.date.accessioned2018-08-24T13:39:36Z
dc.date.available2018-08-24T13:39:36Z
dc.date.issued2018-07-02
dc.identifier.citationReyad, AA., Mishriky, R. (2018) 'Iloperidone - new second generation antipsychotic: Pharmacological aspects and schizophrenia clinical management', International Journal of Current Medical and Pharmaceutical Research,
dc.identifier.issn2395-6429
dc.identifier.doi10.24327/23956429.ijcmpr20180476
dc.identifier.urihttp://hdl.handle.net/2436/621636
dc.description.abstractIloperidone is a new atypical antipsychotic drug approved by FDA for the treatment of schizophrenia. In this article, we searched the published randomized controlled trials (RCT) and other literature to review the efficacy and safety of iloperidone using the following database (Science Direct, PubMed) and illustrate its role in the management of schizophrenia. Iloperidone showed efficacy by causing significant improvements in psychiatric scales such as Positive and Negative Syndrome scale (PANSS) and clinical global impressions (CGI). Iloperidone was associated with a number of common side effects such as metabolic and cardiovascular side effects. This review illustrated that iloperidone was well tolerated with significant improvements in disease severity and symptom intensity control in patients suffering with schizophrenia, however, iloperidone was associated with a significantly higher risk of metabolic and cardiovascular side effects with minimal extrapyramidal side effects. These findings would guide psychiatrists and pharmacists in their clinical role for supporting the care of psychiatric patients.
dc.formatapplication/PDF
dc.language.isoen
dc.publisherVillupuram : journalcmpr
dc.relation.urlhttps://journalcmpr.com/issues/iloperidone-new-second-generation-antipsychotic-pharmacological-aspects-and-schizophrenia
dc.subjectIloperidone
dc.subjectatypical antipsychotic
dc.subjectschizophrenia
dc.subjectpsychiatrists
dc.subjectpharmacists
dc.subjectside effects
dc.titleIloperidone - new second generation antipsychotic: Pharmacological aspects and schizophrenia clinical management
dc.typeJournal article
dc.identifier.journalInternational Journal of Current Medical and Pharmaceutical Research
dc.date.accepted2018-05-24
rioxxterms.funderUniversity of Wolverhampton
rioxxterms.identifier.projectUOW240918AR
rioxxterms.versionAM
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2018-06-28
dc.source.volume4
dc.source.issue6
dc.source.beginpage3420
dc.source.endpage3424
refterms.dateFCD2018-08-24T13:39:37Z
refterms.versionFCDAM
refterms.dateFOA2018-08-24T13:39:37Z


Files in this item

Thumbnail
Name:
Iloperidone IJCMPR.pdf
Size:
205.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/